PT-141 clinical trials: what the Vyleesi studies actually show

Last updated 2026-07-25

What were the RECONNECT trials and what did they test?

RECONNECT is the name given to the two identical phase 3 studies that formed the core evidence package for bremelanotide's FDA approval. Both were randomized, double-blind, placebo-controlled trials in premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD), and together they enrolled more than 1,200 participants ^[1]. Women self-injected either bremelanotide or placebo subcutaneously, as needed, roughly 45 minutes before anticipated sexual activity, for 24 weeks. The two co-primary endpoints were change in desire (measured by the Female Sexual Function Index desire domain) and change in the number of distressing low-desire events, tracked with a daily diary called the FSDS-DAO (Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13) ^[1]. This is the study that regulators leaned on. It's worth reading the primary source directly if you want the actual tables rather than a summary: the trial report was published in Obstetrics and Gynecology in 2019 ^[1]. A later paper pooled and reanalyzed subgroups from both studies to check whether age, menopause proximity, or baseline severity changed the response, which is a useful companion read if you want the more granular numbers ^[2].

How much did desire actually improve in the trials?

In the pooled RECONNECT data, women on bremelanotide had a statistically significant increase in desire score and a decrease in distress compared to placebo, but the absolute difference was small on the rating scales used ^{[1] [3]}. This is where the debate starts. A 2024 reanalysis published in the Journal of Sex Research argued that the between-group differences, while statistically significant, may fall short of what most clinicians would consider a meaningful change for an individual patient, and questioned whether the trials' chosen endpoints capture something patients actually notice in daily life ^[4]. An earlier reanalysis in the same journal made a similar point about how the original trials defined and reported responder thresholds . On the other side, the drug's own program data (including a phase 2b dose-ranging study) found that a meaningful fraction of women who received bremelanotide met the pre-specified "responder" definition for improved desire and reduced distress, more than on placebo ^[5]. So the honest summary is: the effect is real and statistically reproducible across two large trials, but it's modest, and reasonable clinicians disagree about how much day-to-day difference it makes for the average patient. Nobody has a study that resolves this argument; it comes down to how you weigh a small average effect against a real minority of clear responders.

How does PT-141 work differently from Viagra-type drugs in these trials?

This is the single most important thing to understand about the trial design and the drug's action. Bremelanotide is a melanocortin receptor agonist that works in the brain, not a vasodilator that works in blood vessels ^{[6] [7]}. Sildenafil and its relatives increase blood flow to the genitals by blocking an enzyme (PDE5) in vascular smooth muscle. That's a local, physical effect, useful for erectile blood flow but not built to touch desire itself. Bremelanotide instead binds melanocortin 4 receptors (MC4R), largely in the hypothalamus, a brain region tied to sexual motivation ^{[6] [7]}. It doesn't need intact vascular response to work, and it doesn't act on demand for a physical arousal problem the way a PDE5 inhibitor does. This central mechanism is why bremelanotide was tested and approved for a desire disorder (HSDD) rather than for genital arousal or lubrication problems, and it's also why its side effect profile (nausea, flushing, headache, sometimes blood pressure changes) looks different from a vascular drug's side effects ^{[8] [7]}. If you want the deeper receptor biology, the melanocortin system review in Nature Reviews Endocrinology covers how these receptors are also being targeted for metabolic and appetite conditions, which is a separate line of research from the sexual desire indication ^[9]. For a plain explainer of the mechanism itself, see pt 141 peptide.

What side effects showed up in the clinical trials?

Nausea was the most common adverse event across the bremelanotide development program, and flushing was second. A pooled safety analysis across the full clinical program (more than RECONNECT) is the most reliable source here ^[8]. | Adverse event | Approximate frequency in trials |

When was bremelanotide approved and what is it approved for?

The FDA approved bremelanotide under the brand name Vyleesi in 2019, specifically for acquired, generalized hypoactive sexual desire disorder in premenopausal women, taken as-needed by subcutaneous injection ^{[12] [13]}. This was a narrow approval. "Acquired" means the low desire developed after a period of normal desire (it isn't lifelong). "Generalized" means it isn't limited to one partner or one situation. It is not approved for men, for postmenopausal women, or for desire problems tied to a specific relationship or a diagnosable separate cause like depression or a medication side effect ^{[13] [14]}. The approval made bremelanotide the second FDA-approved drug for HSDD, following flibanserin (Addyi) in 2015. A widely cited critique in Drug and Therapeutics Bulletin argues that both approvals rested on trial evidence with effect sizes that are small relative to the side effect burden, and questions whether either drug should be treated as a precedent-setting model for future approvals in this space ^[15]. That's a minority but serious clinical viewpoint worth knowing about before assuming approval equals a strong effect.

How is HSDD diagnosed in these trials, and does that matter?

Trial participants had to meet criteria for HSDD, meaning persistently low sexual desire that causes personal distress, more than low desire on its own. A 2021 review in the Journal of Midwifery & Women's Health lays out the diagnostic framework clinicians use, including ruling out other causes like relationship problems, depression, or medication side effects before diagnosing HSDD ^[16]. This distinction matters for reading the trial results. The drug was tested in women who already met a specific diagnostic bar, not in the general population of women with any dip in desire. If your low desire is tied to a new medication, a relationship conflict, or untreated depression, the RECONNECT trial population doesn't necessarily represent you, and a prescriber should be screening for those causes first ^{[16] [14]}.

What do independent reviews and meta-analyses conclude?

Several independent review articles, not funded by the drug's original trials, have weighed in since approval, and their tone is more measured than a marketing summary would suggest. A 2022 review in Current Psychiatry Reports covering pharmacotherapy options for female sexual dysfunction places bremelanotide alongside flibanserin as one of two approved options, describing modest efficacy with a meaningful side effect burden ^[17]. A separate 2022 review in Current Opinion in Obstetrics & Gynecology reaches a similar conclusion, framing bremelanotide as one reasonable option among several, not a clear first choice for every patient ^[18]. An Expert Opinion on Pharmacotherapy evaluation from 2023 walks through the injection-based dosing model and reiterates that patient selection (correctly diagnosed HSDD, no uncontrolled hypertension) drives who actually benefits ^[19]. A 2022 CNS Spectrums paper focused specifically on the neurobiology angle, reinforcing that the drug's centrally-acting, non-hormonal mechanism is what differentiates it from the earlier, hormone-based approaches to HSDD that dominated the field before 2015 ^[7]. Read together, the field's consensus seems to be: real drug, real mechanism, worth having as an option, modest average effect, not a fix for every case of low desire.

What happened in the earlier phase 1 and phase 2 studies?

Before RECONNECT, bremelanotide (originally studied as PT-141) went through earlier-phase testing that shaped the final dose and delivery method. Early formulations were actually tested as a nasal spray, not an injection ^{[20] [15]}. That nasal formulation was dropped after safety concerns, including blood pressure increases severe enough to change the development path toward the lower-dose, subcutaneous injection now used in Vyleesi ^{[20] [15]}. A phase 2b dose-ranging study helped establish the 1.75 mg subcutaneous dose that eventually went into the phase 3 program, using responder-analysis methods to compare different dose levels ^[5]. There's also a body of earlier phase 1 work looking at bremelanotide's effect on body weight in obese women, since melanocortin receptor activity is tied to appetite regulation as well as sexual desire. Those studies found weight-related effects worth studying further, but that's a separate research thread from the HSDD indication and isn't what Vyleesi is approved for . For dosing specifics relevant to the current approved product, see PT-141 dosage and PT-141 cycle length.

Does bremelanotide's trial data apply to off-label or compounded use?

This needs a direct answer: no, not automatically. The FDA-reviewed trial data covers the approved Vyleesi product, its specific 1.75 mg subcutaneous dose, its specific delivery device, and its specific approved population (premenopausal women with HSDD) ^{[12] [13]}. Bremelanotide is sometimes sold or compounded outside that approved pathway, including for uses like general libido enhancement in men or unapproved combination protocols. The FDA's bulk drug substance rules under 21 CFR 216.23 and 216.24 govern what active ingredients compounding pharmacies may legally use under sections 503A and 503B of the FD&C Act, and bremelanotide's regulatory status in compounding contexts is a separate legal question from its approval as Vyleesi [FDA bulk substances page]. None of the RECONNECT safety or efficacy data was generated in men, and no phase 3 trial has established a dose or safety profile for male sexual dysfunction indications. If a product isn't the FDA-approved Vyleesi pen with FDA-reviewed labeling, the clinical trial numbers in this article don't automatically transfer to it, and dosing, purity, and monitoring become the prescriber's and pharmacy's responsibility rather than something backed by a phase 3 program.

What does the FDA drug label actually say, and where can you verify it?

The Vyleesi label and its approval history are public and searchable through Drugs@FDA, the FDA's official database of approved drug products [Drugs@FDA]. This is the primary source to check for the current prescribing information, including the boxed warnings, dosing instructions, and contraindications, rather than relying on secondary summaries. A 2019 approval summary published in the journal Drugs, part of a "First Approval" series that tracks new drug entries, gives a compact overview of the regulatory timeline and the data package the FDA reviewed ^[12]. A separate pharmacology-focused review in The Annals of Pharmacotherapy from 2020 walks through the label's dosing limits (including a maximum of 8 doses per month, and stopping if no improvement after 8 weeks) in more clinical detail than the original trial papers do ^[13]. Checking the label directly matters because dosing rules, monitoring requirements, and contraindication language can be updated after approval, and a five-year-old journal summary won't reflect a label update.

Frequently asked questions

How many people were in the bremelanotide phase 3 trials?

The two RECONNECT phase 3 trials enrolled more than 1,200 premenopausal women combined, all diagnosed with hypoactive sexual desire disorder. Both were randomized, double-blind, and placebo-controlled over 24 weeks, using subcutaneous self-injection of either bremelanotide or placebo as needed before anticipated sexual activity ^[1].

Did bremelanotide work better than placebo in the trials?

Yes, statistically. Women on bremelanotide showed a significant increase in desire scores and reduction in related distress compared to placebo ^[1][14]. But independent reanalyses have questioned whether the size of that difference is large enough to matter clinically for the average patient, even though it was statistically real ^[21][24].

What is the most common side effect seen in the trials?

Nausea, reported in a large share of treated participants across the development program, often cited near 40% ^[5][17]. Flushing was the second most common. Nausea tended to be strongest with the first dose and often eased with continued use, but it was still the leading reason patients discontinued treatment in trials ^[5].

Is PT-141 the same thing as Vyleesi?

PT-141 was the research code name for bremelanotide during early development. Vyleesi is the FDA-approved brand name for the same molecule, formulated as a 1.75 mg subcutaneous injection and approved in 2019 for hypoactive sexual desire disorder in premenopausal women ^[4][8].

Why is PT-141 not compared directly to Viagra in these trials?

Because they treat different problems through different mechanisms. Sildenafil (Viagra) increases genital blood flow through a vascular pathway and is approved for erectile dysfunction. Bremelanotide acts on melanocortin receptors in the brain to affect desire, and it was tested specifically for a desire disorder, not a blood-flow problem ^[7][19].

Does bremelanotide raise blood pressure in the trials?

Yes, it causes a transient increase in blood pressure after dosing, which is why it isn't recommended for women with uncontrolled hypertension or known cardiovascular disease ^[5][23]. This was monitored closely in the RECONNECT trials, and prescribers are expected to screen for cardiovascular risk before starting it.

How long did the RECONNECT trials last?

Each of the two RECONNECT phase 3 studies ran for 24 weeks of treatment, with participants using bremelanotide or placebo as needed rather than on a fixed daily schedule, followed by assessment of desire scores and distress using validated questionnaires ^[1].

Was bremelanotide ever tested as a nasal spray?

Yes, earlier development explored an intranasal formulation, but it was discontinued after safety concerns, including blood pressure effects that were considered too risky for that delivery route. Development then shifted toward the lower-dose subcutaneous injection that became Vyleesi ^[3][15].

Do the trials show bremelanotide working for men?

No. All FDA-reviewed phase 3 efficacy and safety data for bremelanotide come from premenopausal women diagnosed with HSDD. No phase 3 trial has established an approved dose, efficacy claim, or safety profile for male sexual dysfunction, so any male use sits outside the approved evidence base ^[1][4].

What percentage of women responded to treatment in the trials?

Responder rates varied depending on which endpoint and threshold a given analysis used. A phase 2b dose-ranging study used pre-specified responder definitions to compare doses, and later reanalyses have disputed how meaningful those thresholds are in practice, so a single clean percentage is hard to state without picking a specific paper's definition ^[21][22][24].

Are there criticisms of how the trials measured success?

Yes. Independent reanalyses published in the Journal of Sex Research have specifically challenged the trials' chosen endpoints and responder definitions, arguing the statistically significant results may not reflect a difference most patients would notice day to day ^[21][24]. This remains an active point of debate among researchers, not a settled question.

Does insurance cover Vyleesi based on the trial results?

Trial results support FDA approval, but coverage decisions are made separately by individual insurers and aren't standardized. Coverage for Vyleesi varies by plan, and cost is a common reason patients discuss options with a prescriber before starting; check with your specific insurer rather than assuming trial approval guarantees coverage.

Sources

1. Obstetrics and Gynecology, 2019 (PMID 31599840): Two RECONNECT phase 3 trials enrolled over 1,200 premenopausal women with HSDD and found significant improvement in desire and distress versus placebo over 24 weeks
2. Journal of Midwifery & Women's Health, 2021 (PMID 34510696): HSDD diagnosis requires persistent low desire causing distress, with other causes like relationship issues or depression ruled out first
3. Bremelanotide, 2006 (PMID 31369224): Early bremelanotide development included an intranasal formulation that was discontinued due to blood pressure safety concerns
4. Bremelanotide: First Approval, Drugs, 2019 (PMID 31429064): Bremelanotide was approved by the FDA in 2019 as Vyleesi for premenopausal women with acquired, generalized HSDD
5. Safety Profile of Bremelanotide Across the Clinical Development Program, Journal of Women's Health, 2022 (PMID 35147466): Nausea and flushing were the most common adverse events across the pooled bremelanotide clinical trial program, with transient blood pressure increases also documented
6. Targeting the central melanocortin system for metabolic disorders, Nature Reviews Endocrinology, 2023 (PMID 37365323): Melanocortin receptors, the same receptor family bremelanotide targets, are also under research for metabolic and appetite regulation
7. Bremelanotide for Treatment of Female Hypoactive Sexual Desire, Neurology International, 2022 (PMID 35076581): Bremelanotide acts as a melanocortin receptor agonist with a central nervous system mechanism distinct from vascular-acting drugs
8. The Annals of Pharmacotherapy, 2020 (PMID 31893927): Vyleesi is approved specifically for premenopausal women with HSDD, dosed as a subcutaneous injection with defined monthly dosing limits
9. The Urologic Clinics of North America, 2022 (PMID 35428435): Treatment approaches for female sexual dysfunction require distinguishing HSDD from other causes of low desire before selecting pharmacotherapy
10. Current Psychiatry Reports, 2022 (PMID 35102537): Independent review places bremelanotide alongside flibanserin as one of two FDA-approved options for female sexual dysfunction with modest efficacy
11. Current Opinion in Obstetrics & Gynecology, 2022 (PMID 36036468): Independent review frames bremelanotide as one reasonable pharmacologic option among several for sexual dysfunction, not a universal first choice
12. Expert Opinion on Pharmacotherapy, 2023 (PMID 36242769): Evaluation of bremelanotide injection emphasizes patient selection, including correct HSDD diagnosis and absence of uncontrolled hypertension, as key to treatment benefit
13. Prespecified and Integrated Subgroup Analyses from RECONNECT, Journal of Women's Health, 2022 (PMID 35230162): Pooled subgroup analysis of the RECONNECT trials examined how age and baseline severity affected response to bremelanotide
14. Melanocortins in the treatment of male and female sexual dysfunction, Current Topics in Medicinal Chemistry, 2007 (PMID 17584134): Early melanocortin agonist development for sexual dysfunction included nasal delivery routes before shifting to injectable formulations
15. CNS Spectrums, 2022 (PMID 33455598): Bremelanotide's centrally-acting, non-hormonal mechanism differentiates it from earlier hormone-based HSDD treatments
16. The Medical Letter on Drugs and Therapeutics, 2019 (PMID 31381550): Independent drug bulletin review confirms nausea as a common and clinically significant tolerability issue for Vyleesi
17. Drug and Therapeutics Bulletin, 2021 (PMID 34642243): Critique argues both flibanserin and bremelanotide approvals rest on trial evidence with effect sizes small relative to side effect burden
18. Journal of Sex Research, 2024 (PMID 36809187): Reanalysis argues the statistically significant RECONNECT trial results may not represent a clinically meaningful difference for the average patient
19. The Journal of Sexual Medicine, 2019 (PMID 31277966): Phase 2b dose-ranging study used pre-specified responder analyses to help establish the 1.75 mg dose used in phase 3 trials
20. Medicina (Kaunas), 2022 (PMID 35630054): Review of hypertension and female sexual dysfunction treatment notes bremelanotide is not recommended for patients with uncontrolled high blood pressure
21. Journal of Sex Research, 2021 (PMID 33678061): Reanalysis of the phase 3 bremelanotide trials challenges how responder thresholds and endpoints were originally defined and reported
22. Diabetes, Obesity & Metabolism, 2022 (PMID 35170192): Phase 1 trials found bremelanotide had measurable effects on body weight in obese women, a separate research thread from the HSDD indication